17,261 trials
Melanoma
Primary: Objective Response Rate (ORR) in the Full Analysis Set Analysis Population — 45.0 Percentage of participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Blasts Under 10 Percent of Bone Marrow Nucleated Cells
Primary: Recurrence-free Survival Rate — 8.5 Months
Adenomatous Polyposis Coli
Primary: Change in Marked Polyp Size — 16; 4; 0 Size of marked polyps
Liver Transplant; Complications · NAFLD
Primary: Number of Participants With Adverse Events Assessed by CTCAE — 12 Participants
Alcohol Use Disorder (AUD) · Substance Use Disorders
Primary: Change in Number of Substance Use Occasions — -11.3; -11.2; -13.6; -12.9 occasions
Non-Alcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16 — -26.2; -27.0; -44.9; 2.6 Percentage change — p=0.0002
Depressive Disorder, Major
Primary: Percentage Change of the BOLD Signal — -0.08; 0.43 percentage change in BOLD signal
Cutaneous Lichen Planus
Primary: Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) at Week 16 — 50.0; 21.9 percentage of participants — p=0.0129
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Genetic Obesity
Primary: Stage 1: Number of Participants by Genotype Who Demonstrated a Significant Clinically Meaningful Response to Setmelanotide at the End of Stage 1 — 49; 0; 0; 2 Participants
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube High Grade Serous Adenocarcinoma
Primary: Dose-limiting Toxicities (Phase I) — 2; 3 participants
Telangiectasia, Hereditary Hemorrhagic
Primary: Change From Baseline Epistaxis Severity Score — -1; -1.1; -1.3; -1.2 units on a scale
Rectal Cancer
Primary: Number of Participants With Disease Recurrence — 53; 39 Participants — p=0.047
Cardiovascular Risk Reduction
Primary: Arterial Stiffness — 10.1; 14.8; 6.4; 12.7 mm Hg
Non Small Cell Lung Cancer
Primary: Change in the Mean Number of Infiltrating Absolute Cluster of Differentiation 3 (CD3+) T Cells/ μm2 — 2976.00007; 3768.74373 CD3+ T cells/ μm2